Related Experiment Videos
Ribociclib: First Global Approval
1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Abstract:
Ribociclib is an oral, small-molecule inhibitor of cyclin-dependent kinase (CDK) 4 and 6 that is under development by Novartis for the treatment of cancer. CDKs play an important role in cell cycle progression and cellular proliferation, and inhibition of these kinases with ribociclib results in G1 phase cell-cycle arrest. Ribociclib, in combination with an aromatase inhibitor, was recently approved in the USA for the first-line treatment of advanced breast cancer and has been submitted for approval in the EU for this indication. Ribociclib is undergoing further phase III investigations in breast cancer and is being evaluated in phase I or II trials for various solid tumour types and haematological malignancies. This article summarizes the milestones in the development of ribociclib leading to this first global approval for use as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
Insights
Ribociclib, a CDK 4/6 inhibitor, offers a new treatment for advanced breast cancer. This oral medication, when combined with endocrine therapy, halts cancer cell growth by arresting the cell cycle.
Area of Science:
- Oncology
- Pharmacology
Background:
- Cyclin-dependent kinases (CDK) 4 and 6 are crucial regulators of cell cycle progression.
- Dysregulation of CDK4/6 is implicated in various cancers, including breast cancer.
- Targeting CDK4/6 offers a therapeutic strategy for cell cycle control in cancer.
Purpose of the Study:
- To summarize the development milestones of ribociclib.
- To highlight the first global approval of ribociclib for advanced breast cancer.
- To detail its mechanism of action as a CDK4/6 inhibitor.
Main Methods:
- Ribociclib is an oral small-molecule inhibitor targeting CDK4 and CDK6.
- Its mechanism involves inducing G1 phase cell-cycle arrest.
- Clinical development includes Phase I, II, and III trials across various cancer types.
Main Results:
- Ribociclib, combined with an aromatase inhibitor, received US FDA approval for first-line treatment of HR+, HER2- advanced breast cancer.
- Submission for EU approval for the same indication is complete.
- Ongoing investigations explore its efficacy in other solid tumors and hematological malignancies.
Conclusions:
- Ribociclib represents a significant advancement in breast cancer therapy.
- Its approval marks a milestone in targeted endocrine-based treatment for postmenopausal women.
- Further research is evaluating its broader application in oncology.